MCK Jan 2024 200.000 put
| Previous close | 0.8000 |
| Open | 0.8300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 200.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.8000 - 0.8300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley FoolIf You Invested $20,000 in McKesson in 2018, This Is How Much You Would Have Today
McKesson (NYSE: MCK) is one of the largest pharmaceutical distributors in the country. While this isn't the type of investment you might expect 10x returns from, it can provide stability and even reliable dividend income. On the first day of trading in 2018, shares of McKesson closed at $159.
Motley FoolWorried About a Recession? 2 Safe Stocks to Buy Now
You may know Pfizer (NYSE: PFE) for its blockbuster coronavirus vaccine. Pfizer may face a bit of a near-term slowdown in revenue. In fact, Pfizer says these launches should result in $20 billion in sales in 2030.
Motley FoolWarren Buffett Has Nearly $1 Billion in This Healthcare Stock: Should You Buy It?
This company is the largest player in the medical distribution industry and is featured in Berkshire Hathaway's investment portfolio.
Motley Fool5 Stocks You Can Confidently Invest $500 in Right Now
You don't have to worry about pinpointing an entry point if the underlying company is truly built to last.
ZacksMcKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
Motley Fool2 Warren Buffett Stocks to Buy Hand Over Fist in May
It has been said many times before, and it will be many times again: Warren Buffett is the greatest investor of all time. Among the many world-class businesses in Berkshire Hathaway's $345.4 billion investment portfolio, here are two that I think dividend growth investors should strongly consider buying this month. It's no secret that Buffett and his business partner Charlie Munger prefer to invest in businesses that are profitable and possess competitive moats.
Motley FoolMcKesson (MCK) Q4 2023 Earnings Call Transcript
At this time, I would like to turn the call over to Nicole Kramer, manager of investor relations. Today, I'm joined by Brian Tyler, our chief executive officer; and Britt Vitalone, our chief financial officer.
ZacksMcKesson (MCK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksMcKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
McKesson (MCK) delivered earnings and revenue surprises of 0.42% and 1.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireMcKesson Corporation Reports Fiscal 2023 Fourth-Quarter and Full-Year Results and Raises Long-Term Segment Growth Targets
IRVING, Texas, May 08, 2023--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 fourth-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
ZacksHere's How Inter Parfums (IPAR) is Placed Ahead of Q1 Earnings
Inter Parfums' (IPAR) Q1 earnings are expected to reflect gains from robust top-line growth, strength across brands, expansions and product launches.
ZacksMcKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Motley FoolThese Have Been 3 of the Best-Performing Healthcare Stocks Since 2020
The COVID-19 public health emergency is slated to end in the U.S. on May 11. Three of the best-performing healthcare stocks since then include Moderna (NASDAQ: MRNA), McKesson (NYSE: MCK), and Eli Lilly (NYSE: LLY). It has multiple products in its approval pipeline, including a vaccine for the respiratory syncytial virus that has been highly effective in late-stage trials.
ZacksStaar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksMcKesson (MCK) Gains As Market Dips: What You Should Know
In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.
ZacksSmileDirectClub (SDC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIs a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
ZacksMcKesson (MCK) Earnings Expected to Grow: Should You Buy?
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksHow to Find Strong Medical Stocks Slated for Positive Earnings Surprises
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Motley FoolWorried About a Recession? 2 Resilient Stocks to Buy Now
The healthcare industry is a great place to find stocks that can perform well under any economic conditions.
ZacksWhat's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
Business WireMcKesson Corporation Declares Quarterly Dividend
IRVING, Texas, April 27, 2023--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on July 3, 2023, to stockholders of record on June 1, 2023.
Motley FoolCould McKesson Stock Help You Become a Millionaire?
You may have come into contact many times with McKesson (NYSE: MCK) without even realizing it. The healthcare company doesn't develop drugs, but it distributes a lot of the pharmaceutical products sold today. The company has increased revenue over time and delivered gains in free cash flow.
ZacksMcKesson (MCK) Dips More Than Broader Markets: What You Should Know
In the latest trading session, McKesson (MCK) closed at $359.24, marking a -1.11% move from the previous day.
ZacksConmed (CNMD) Beats Q1 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 10% and 10.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?